The Top 10 Revenue Streams Independent Pharmacies Are Adding in 2026

Independent pharmacy gross profit margin fell to 18.2 percent in 2024, down from 19.7 percent the year before, the lowest point in the NCPA Digest's tracking, and margins have fallen every year since 2019 outside the 2021 COVID vaccine bump.

That is the actual reason dispensing alone no longer works as a business model. The most profitable independent pharmacies are not filling more prescriptions, they are diversifying how and why they get paid. Below are the ten revenue streams showing up most often across profitable independents, ranked by real-world adoption and margin potential.

Some of these depend on state regulations, payer participation, and local market dynamics, so not every option fits every pharmacy. The goal is not to add all ten. It is to know what is actually on the table before deciding what to leave off.

1. Paid clinical services and value-based payer programs

   
   

   This breaks the dependence on dispensing margin directly. Pharmacies participating in payer-sponsored clinical programs get paid for outcomes, adherence, and patient engagement, revenue that does not move with PBM reimbursement pressure the way prescription margin does.

   
   

2. Immunizations beyond flu season

   
   

   93 percent of independent pharmacies administered flu immunizations and 92 percent administered non-flu immunizations in 2024, per the NCPA Digest. Profitable pharmacies treat immunizations as a year-round clinical offering, not a seasonal side project, since non-flu vaccines often carry better margins.

   
   

3. Point-of-care testing and test-and-treat services

   
   

   45 percent of independent pharmacies offered point-of-care testing in 2024. The most common tests are influenza, blood glucose, and hemoglobin A1c, each offered by about half of pharmacies doing POCT, with COVID-19 testing still offered by just over half. It combines patient convenience with professional reimbursement, and drives foot traffic that turns the pharmacy into a care destination instead of a pickup counter.

   
   

4. Medication Therapy Management and chronic care services

   
   

   80 percent of independent pharmacies offered MTM in 2024. Profitable pharmacies treat it as foundational rather than optional, and pair it with chronic care support like blood pressure monitoring, offered by 73 percent of independents.

   
   

5. Long-term care services, including LTC at home

   
   

   55 percent of independent pharmacies provided LTC services in 2024, serving an average of 100 beds per skilled nursing facility relationship. LTC at home is the newer piece of this, and the average number of beds served through that model grew more than 10 percent year over year, expanding access to this revenue without requiring a traditional facility relationship.

   
   

6. Specialty pharmacy access or specialty-lite models

   
   

   Only 5 percent of independents held at least one specialty pharmacy contract in 2024, down from 6 percent the year before. Independents have a real competitive advantage in dispensing specialty medications, but specialty pharmacies vertically integrated with payers keep steering patients into mail order. That is exactly why a focused specialty-lite niche beats trying to compete for broad access.

   
   

7. Strategic compounding, even at a limited level

   
   

   45 percent of independent pharmacies offered compounding in 2024, down from 47 percent in 2023 and 62 percent in 2022. Fewer pharmacies are doing it, which is precisely what makes it a differentiator for the ones that do. A full compounding lab is not required. A limited, focused compounding line can create higher-margin revenue and real local separation from competitors who have dropped it.

   
   

8. Durable Medical Equipment and Medicare Part B services

   
   

   Retail DME spend reached 67.1 billion dollars in 2022, about 2 percent of total U.S. health spending, and demand is rising as the population over 65 grows past 61 million. DME is paperwork-heavy, which is exactly why many pharmacies avoid it and leave the opportunity to those willing to operationalize it properly.

   
   

9. 340B contract pharmacy partnerships

   
   

   22 percent of independent pharmacies participated in 340B contract pharmacy arrangements as of 2022, well below participation rates among large chains. Where available, it can materially impact revenue, but it is situational and carries real compliance requirements that need to be evaluated carefully rather than chased for volume.

   
   

10. Medication synchronization and appointment-based models

    
    

    88 percent of independent pharmacies now synchronize medication refills, and among those that do, 96 percent sync all of a patient's chronic medications to a single monthly pick-up date. It stabilizes operations, improves adherence, and sets the foundation for higher-value clinical services layered on top of it.

    
    

The pattern worth noticing

What ties these together is not complexity, it is intentionality. Profitable pharmacies are not chasing every option on this list. They are selecting a few that improve margin stability, reduce reliance on unpredictable reimbursement, and fit their staffing and patient base.

Many owners already know some of these exist. Fewer have taken the time to evaluate which ones actually make financial sense for their specific pharmacy, and that gap is where frustration builds. Independent pharmacy is not dead, but the model has changed, and owners who recognize that early tend to have more options than they expect.

If you have questions about this topic, speak with your CPA or accountant. And if you need guidance or a second opinion, you’re always welcome to contact us.